Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment (RIOT-A)
Reducing the Impact of Ovarian Stimulation - The RIOT Project. Study RIOT-A: The Role of Aromatase Inhibitor in Reducing the Detrimental Effects of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The aim of the study is to investigate whether the detrimental effects of ovarian stimulation on outcomes in fresh embryo transfer cycles be ameliorated by co-treatment with aromatase inhibitors? The research questions are:
- Can the impact of ovarian stimulation on late follicular phase sex steroid levels (and hence endometrial receptivity) be mitigated by co-treatment with aromatase inhibitors during ovarian stimulation?
- Does co-treatment with aromatase inhibitors 'normalize' the endocrinology of the midluteal phase
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Capital Region
-
Herlev, Capital Region, Denmark, 2730
- Unit of Reproductive Medicine, Herlev Hospital
-
-
Capitol Region
-
Copenhagen, Capitol Region, Denmark, 2100
- Department of Fertility, Juliane Marie Centeret
-
Hvidovre, Capitol Region, Denmark, 2650
- Clinic of Fertility, Hvidovre Hospital
-
-
Region Of Zealand
-
Holbæk, Region Of Zealand, Denmark, 4300
- Clinic of Fertility, Holbæk Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Indication for IVF/ICSI treatment
- Eligible for IVF/ICSI treatment according to local criteria
- Regular cycles 21-35 days (both included)
- Age < 40
- AMH 8- 32 (both included)
- Written consent
EXCLUSION CRITERIA
- Any contraindication for IVF/ICSI treatment according to local criteria
- Previous stimulation for IVF/ICSI with < 4 oocytes obtained
- PCOS
- Undergoing IVF/ICSI for the purpose of fertility preservation
- Allergy towards study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Lactose Monohydrate
2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
|
Adjuvant therapy to recFSH during ovarian stimulation
Other Names:
|
|
Active Comparator: Letrozole 5mg
2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
|
Adjuvant therapy to recFSH during ovarian stimulation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum progesterone level
Time Frame: Assessed during stimulation treatment on day before hCG injection (throughout the study completion, up to 3 years)
|
Assessed during stimulation treatment on day before hCG injection (throughout the study completion, up to 3 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum estradiol, testosterone and androstenedione levels
Time Frame: Assessed on stimulation day 5, day of hCG administration (or the day before), day 7 and 10 after hCG administration. Assessed throughout study completion, up to 3 years.
|
Assessed on stimulation day 5, day of hCG administration (or the day before), day 7 and 10 after hCG administration. Assessed throughout study completion, up to 3 years.
|
|
P and 17-hydroxyprogesterone (17-HP) Area Under the Curve.
Time Frame: Assessed during stimulation treatment throughout the study completion, up to 3 years.
|
Assessed during stimulation treatment throughout the study completion, up to 3 years.
|
|
Follicular fluid concentration of estradiol, testosterone, inhibin B and AMH levels
Time Frame: Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
|
Total IU of Follicle Stimulating Hormone used per cycle.
Time Frame: Assessed throughout study completion, up to 3 years
|
Assessed throughout study completion, up to 3 years
|
|
Number of follicles > 12 mm
Time Frame: Assessed in stimulated cycle on day of hCG administration or the day before (throughout the study completion), up to 3 years. Cycle length is between 21 and 35 days
|
Assessed in stimulated cycle on day of hCG administration or the day before (throughout the study completion), up to 3 years. Cycle length is between 21 and 35 days
|
|
Number of oocytes obtained oocytes obtained.
Time Frame: Assessed in stimulated cycle at time of oocyte pick up after follicle aspiration (throughout the study completion, up to 3 years).Cycle length is between 21 and 35 days
|
Assessed in stimulated cycle at time of oocyte pick up after follicle aspiration (throughout the study completion, up to 3 years).Cycle length is between 21 and 35 days
|
|
Proportion of oocytes resulting in top quality day 2, day 3 embryos or day 5/6 embryos according to validated morphological criteria.
Time Frame: Assessed at day 2-3 after oocyte pick up following stimulation (throughout study completion, up to 3 years)
|
Assessed at day 2-3 after oocyte pick up following stimulation (throughout study completion, up to 3 years)
|
|
Oocyte fertilization rate
Time Frame: Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
|
Number and quality of embryos obtained, including rate of blastocyst formation.
Time Frame: Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
|
Endometrial thickness in millimeters
Time Frame: Assessed throughout the study completion, up to 3 years
|
Assessed throughout the study completion, up to 3 years
|
|
Implantation rate
Time Frame: Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
Assessed during stimulation treatment (throughout the study completion, up to 3 years
|
|
Biochemical pregnancy rate
Time Frame: Assessed 2 weeks after embryo transfer following stimulation (throughout study completion, up to 3 years)
|
Assessed 2 weeks after embryo transfer following stimulation (throughout study completion, up to 3 years)
|
|
Clinical pregnancy rate
Time Frame: Pregnancy scan at gestational age week 7-8 (3-4 weeks after the positive hCG in serum). Assessed throughout study completion, up to 3 years.
|
Pregnancy scan at gestational age week 7-8 (3-4 weeks after the positive hCG in serum). Assessed throughout study completion, up to 3 years.
|
|
Morphokinetic parameters of embryo quality as measured using a Time Lapse analysis in centers employing this technology.
Time Frame: Assessed from time of oocyte pick-up to embryo transfer following stimulation (throughout study completion, up to 3 years)
|
Assessed from time of oocyte pick-up to embryo transfer following stimulation (throughout study completion, up to 3 years)
|
|
Reported side effects
Time Frame: From start of stimulation and administration of study medication to pregnancy scan week gestational age 7-8. Assessed throughout study completion, up to 3 years.
|
From start of stimulation and administration of study medication to pregnancy scan week gestational age 7-8. Assessed throughout study completion, up to 3 years.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RIOTA2015
- 2015-005682-24 (EudraCT Number)
- H-15021850 (Other Identifier: Ethics Committee)
- HGH-2016-045_04513 (Other Identifier: Danish Data Protection Board)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.